Treatment | Page 380 of 465

Health :: Key mechanism by which lethal viruses ebola and marburg cause disease

Researchers in the Greene Infectious Disease Laboratory at Columbia University’s Mailman School of Public Health, the Centers for Disease Control and Prevention, and the Caribbean Primate Research Center have discovered a key mechanism by which the Filoviruses, Ebola and Marburg, cause disease. The identification of an amino acid sequence in Filoviruses that results in the rapid depression of immunological response is described in the December 2006 issue of The FASEB Journal. Using this information, researchers can begin to develop new drugs to stop these devastating diseases.

HIV :: Virco introduces an improved rapid methodology to establish new hiv-1 resistance profiles

Responding to the need to make timely evaluations and decisions when treating treatment experienced HIV patients, Virco (http://www.vircolab.com), a leader in drug resistance testing recently introduced an improved virco(R)TYPE HIV-1 test that rapidly determines the complex phenotypic resistance profiles for darunavir, tipranavir and other antiretroviral (ARV) drugs. Utilizing clinical trial data that was used to support the approval of darunavir and tipranavir, virco(R)TYPE HIV-1 reports now include Clinical Cut-Offs (CCOs) for these recently introduced agents(1). Virco(R)TYPE HIV-1 analyzes patient HIV-1 resistant genotypes using Virco’s large database to quickly and accurately predict phenotypic resistance. This timely determination of phenotypic resistance assists physicians in choosing a drug treatment plan that has the least amount of drug resistance.

Health :: New mechanism found that may underlie neuropathic pain

Researchers at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) announced on 15 October 2006 that they have discovered a new molecular mechanism that may underlie neuropathic pain. The clearer understanding of the root-cause of chronic neuropathic pain, and the preclinical validation of new targets for pharmaceutical therapies shown in this research, together present an opportunity for the development of new ways to treat the severe pain associated with such common conditions or diseases as sciatica, diabetic neuropathy and shingles.

Diabetes :: Novartis GALIANT study – clinical trials for diabetes drug Galvus – vildagliptin

Novartis announced the start of GALIANT, a significant clinical trial set to involve more than 7,500 people in the United States comparing the investigational oral type 2 diabetes medication Galvus? (vildagliptin) with commonly prescribed anti-diabetic oral medicines called thiazolidinediones (TZDs).

Brain Tumor :: Children’s hospital Boston neurosurgeons to perform brain tumor removal during live webcast

On Wednesday, Oct. 25, at 1:00 p.m. EDT, neurosurgeons at Children’s Hospital Boston will remove a brain tumor employing functional mapping of the cortex on a 13-year-old pediatric patient during a live Webcast. Children’s hosts three to four Webcasts annually to showcase its pioneering care and technology to specialists and referring physicians around the world, and to educate consumers on the latest and most innovative medical treatments available.

Diet :: Broccoli work to prevent cancer

After all these years, mom was right. She knew broccoli was good for you, she just didn’t know it was this good. “Everyone knows broccoli is good for you and that it contains compounds known to lessen the occurrence of some types of cancer. We want to know how these compounds work and what their specific targets may be,” says Janet V. Cross, Ph.D., Assistant Professor of Pathology at the University of Virginia School of Medicine.

Migraine :: Clinical trial in acute migraine for lead compound tezampanel

TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced the initiation of a Phase IIb clinical trial for its lead product candidate, tezampanel, a novel pain compound in development for the treatment of acute migraine. An AMPA/kainate (AK) receptor antagonist, tezampanel offers a non-narcotic, non-vascular approach to the management of headache pain and represents a potentially promising alternative to current migraine treatments.

Dental Health :: Oragenics reports positive clinical results with its oral probiotic mouthrinse

Oragenics, Inc. (Amex: ONI) announced today that the first of two sets of subjects has completed a clinical trial utilizing its proprietary oral probiotic product, Probiora3(TM). The trial was designed to determine safety and the effectiveness of the mouthrinse against baseline levels of disease-causing bacteria in the mouth. Daily mouth rinsing with Probiora3(TM) resulted in substantial reductions in the numbers of the bacterium, S. mutans, which attacks teeth, as well as two target periodontal strains, Porphyromonas gingivalis and Campylobacter rectus, associated with gum disease and bad breath. The product was well tolerated by the subjects and no safety issues were identified with the twice daily use of the product over a two-month period.

Allergy :: Food allergies could be fought with friendly bacteria in alcoholic milkshake

Feeding babies alcoholic milk may help to protect against some food allergies. Kefir, a traditional fermented drink, is consumed in Eastern Europe as a health food, and is often used to wean babies, as it is easily digested. Food allergy prevalence is especially high in children under the age of three, with around 5-8% of infants at risk. Currently the only treatment is avoidance of the problematic food.

Health :: Using neurofeedback to aid medical patients

A new article reviews the literature of quantitative electroencephalography (QEEG) that documents abnormal brain wave patterns accompanying several medical conditions. The research implies that neurofeedback training may partially or fully normalize these brain wave patterns, and improve the physical and mental functioning of people with these conditions. The article is in the latest issue of Biofeedback.